Fig. 8
From: Targeting epigenetic features in clear cell sarcomas based on patient-derived cell lines
PRMT inhibitor treatment and ArgMet profiles: viability determination of MUG Lucifer prim and MUG Lucifer met cells treated with 0–10 µM GSK 3368715 for six days normalized to the DMSO control. IC50 was calculated using GraphPad Prism 9. Error indicators are the positive and negative standard deviations based on biological replicates (n = 3) (A). Viability determination of MUG Lucifer prim and MUG Lucifer met cells treated with 0–10 µM GSK 591 for six days normalized to the DMSO control. Error indicators are the positive and negative standard deviations based on biological replicates (n = 3) (B). Viability determination of MUG Lucifer prim and MUG Lucifer met cells treated with 0–20 µM AdOx for 72 h normalized to the DMSO control. IC50 was calculated using GraphPad Prism 9. Error indicators are the positive and negative standard deviations based on biological replicates (n = 3) (C). ADMA/ARG ratios of MUG Lucifer prim cells treated with 3.8 µM GSK 3368715 (IC50) and 6.8 µM AdOx (IC50) and the respective DMSO controls (D). ADMA/ARG ratios of MUG Lucifer met cells treated with 3.8 µM GSK 3368715 (IC50) and 6.8 µM AdOx (IC50) and the respective DMSO controls (E). (SDMA + MMA)/ARG ratios of MUG Lucifer prim cells treated with 3.8 µM GSK 3368715 (IC50) and 6.8 µM AdOx, (IC50) and the respective DMSO controls (F). (SDMA + MMA)ARG ratios of MUG Lucifer met cells treated with 3.8 µM GSK 3368715 (IC50) and 6.8 µM AdOx (IC50) and the respective DMSO controls (G)